Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015624
Filing Date
2024-11-14
Accepted
2024-11-14 08:01:22
Documents
63
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q avbp-20240930x10q.htm   iXBRL 10-Q 1312026
2 EX-10.1 avbp-20240930xex10d1.htm EX-10.1 346630
3 EX-31.1 avbp-20240930xex31d1.htm EX-31.1 15732
4 EX-31.2 avbp-20240930xex31d2.htm EX-31.2 15726
5 EX-32.1 avbp-20240930xex32d1.htm EX-32.1 7778
6 EX-32.2 avbp-20240930xex32d2.htm EX-32.2 7772
  Complete submission text file 0001558370-24-015624.txt   5606576

Data Files

Seq Description Document Type Size
7 EX-101.SCH avbp-20240930.xsd EX-101.SCH 34643
8 EX-101.CAL avbp-20240930_cal.xml EX-101.CAL 28554
9 EX-101.DEF avbp-20240930_def.xml EX-101.DEF 123923
10 EX-101.LAB avbp-20240930_lab.xml EX-101.LAB 317990
11 EX-101.PRE avbp-20240930_pre.xml EX-101.PRE 246360
66 EXTRACTED XBRL INSTANCE DOCUMENT avbp-20240930x10q_htm.xml XML 799439
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41929 | Film No.: 241457295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)